Elan Corporation has appointed Carlos V. Paya, MD, PhD, as president of the company. Dr Paya will be based at Elan’s South San Francisco campus, with particular focus on and responsibility for leading the company’s scientific, clinical and medical initiatives. Dr Paya will also assume responsibility for Elan’s commercial and marketing functions, with a primary focus on strategic planning, marketing positioning and product life cycle management.

Dr Paya joins Elan from Eli Lilly & Company, where he was vice president of Lilly Research Laboratories and global leader of the Diabetes and Endocrine Platform. Prior to his executive career at Lilly, he was a vice dean of Clinical Investigation at the Mayo Clinic.
 

---

Using the buttons below you can save this article to your favourite social bookmarking site